Audit in process? Call the number on your audit letter to get options.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 9, 2018 - Theravance Biopharma and Mylan announced the FDA approval Yupelri (revefenacin), for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Download PDF
Return to publications
